Trial of Roche's drug plus remdesivir didn't meet its endpoints

Thursday, 11. March 2021 08:51

The "phase III REMDACTA trial" of F. Hoffmann-La Roche AG's drug Actemra/RoActemra (tocilizumab) combined with Gilead Sciences Inc.'s Veklury (remdesivir) "did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone," the Swiss company announced on Thursday. The secondary endpoints "included likelihood of death, likelihood of progression to mechanical ventilation or death, and clinical status."

Roche added it will submit the full trial results to a peer-reviewed journal for publication later this year.

"Given the global impact of COVID-19 pneumonia on patients, we are disappointed that the REMDACTA study did not meet its endpoints. We continue to believe that the totality of data suggests a potential role for Actemra in treating certain patients with COVID-19, and will discuss the results with health authorities," Roche's Chief Medical Officer and Head of Global Product Development Levi Garraway noted in a statement.

Related Links: Roche HoldingGilead Sciences Inc.
Breaking the News / MS